Login to Your Account

From Dyslipidemia to Cardiac Risk Prevention

With New SPA for Fish Oil Drug, Amarin is on its Way

By Catherine Shaffer

Thursday, August 11, 2011
Amarin Corp. plc and the FDA have reached an agreement on a special protocol assessment (SPA) for the design of a cardiovascular outcomes study (REDUCE-IT) of AMR101. The drug, a prescription-grade fish oil, has already turned in impressive results for dyslipidemia in two previous Phase III trials.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription